Trial · NCT00579137

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

NCT00579137, Phase 1, Phase 2, Terminated, Baylor College of Medicine; results first posted 2013-07-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders. Trials, record NCT00579137. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00579137

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
NCT number: NCT00579137
Status: Terminated
Phases: Phase 1, Phase 2
Enrollment: 3 participants, actual
Lead sponsor: Baylor College of Medicine
Conditions: Severe Combined Immunodeficiency Disease, Severe Primary Immunodeficiency Disorder, Undefined T Cell Deficiency Disorder, Wiskott-Aldrick Syndrome
Interventions: Campath -1H, Fludarabine, Anti-CD45, Stem cell infusion
First posted: 2007-12-21
Last updated: 2013-07-02
Results first posted: 2013-07-02

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame
Primary	Number of Patients With Donor Engraftment	100 Days
Secondary	Patients Alive at 1 Year	1 Year
Secondary	Number of Patients With Grade III or IV Toxicity	100 days
Secondary	Number of Patients With Grade III to IV Acute GVHD	100 days

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Patients With Donor Engraftment	100 Days	participants	NUMBER
SECONDARY	Patients Alive at 1 Year	1 Year	participants	NUMBER
SECONDARY	Number of Patients With Grade III or IV Toxicity	100 days	participants	NUMBER
SECONDARY	Number of Patients With Grade III to IV Acute GVHD	100 days	participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Patients With Donor Engraftment	Single Group	1	participants
Patients Alive at 1 Year	Single Group	3	participants
Number of Patients With Grade III or IV Toxicity	Single Group	0	participants
Number of Patients With Grade III to IV Acute GVHD	Single Group	0	participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Participants With SCID or Primary Immunodeficiency Disorder	3
Overall Study	COMPLETED	Participants With SCID or Primary Immunodeficiency Disorder	3
Overall Study	NOT COMPLETED	Participants With SCID or Primary Immunodeficiency Disorder	0

Source ClinicalTrials.gov

Adverse events33

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	AST, SGOT(serum glutamic oxaloacetic transaminase)	Metabolism and nutrition disorders	Single Group	1	3	5
other	Albumin, serum-low (hypoalbuminemia)	Metabolism and nutrition disorders	Single Group	1	3	5
other	Allergic reaction/hypersensitivity (including drug fever)	Immune system disorders	Single Group	1	3	1
other	Bronchospasm, wheezing	Respiratory, thoracic and mediastinal disorders	Single Group	1	3	1
other	Calcium, serum-low (hypocalcemia)	Metabolism and nutrition disorders	Single Group	1	3	2
other	Constipation	Gastrointestinal disorders	Single Group	1	3	3
other	Cough	Respiratory, thoracic and mediastinal disorders	Single Group	1	3	3
other	Dermatology/Skin - Other: Livedo reticularis	Skin and subcutaneous tissue disorders	Single Group	1	3	2
other	Diarrhea	Gastrointestinal disorders	Single Group	1	3	5
other	Dry skin	Skin and subcutaneous tissue disorders	Single Group	1	3	1

1 to 10 of 33Source ClinicalTrials.gov

See all 33 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Single Group
Total, other adverse events	Single Group	3	3
Total, serious adverse events	Single Group	0	3

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00579137

GET https://conductscience.org/api/trials/v1/NCT00579137/events?page=2

API reference For AI assistants